Keefer M C, Bonnez W, Roberts N J, Dolin R, Reichman R C
Department of Medicine, University of Rochester School of Medicine and Dentistry, New York 14642.
J Infect Dis. 1991 Mar;163(3):448-53. doi: 10.1093/infdis/163.3.448.
The lymphocyte proliferative responses were studied of 12 volunteers enrolled in a phase I trial of a baculovirus-expressed recombinant human immunodeficiency virus type 1 (HIV-1) envelope glycoprotein (rgp160) vaccine. Six subjects received rgp160 and three subjects each received recombinant hepatitis B vaccine or placebo at 0, 1, and 6 months. rgp160 and a control preparation, baculovirus-expressed recombinant HIV-1 p24, were used as in vitro antigens. At day 56, all rgp160 recipients had stimulation indexes (rgp160/rp24) greater than 3.0, and five of six had differences in counts per minute (cpm) greater than 1000. Stimulation indexes were less than 2.0 and cpm differences were less than 150 in all six who did not receive rgp160. Lymphocyte proliferative responses were first noted 2 weeks to 5 months before initial Western blot reactivity and persisted for greater than or equal to 540 days, even among subjects who lost detectable antibody. Thus, the HIV-1 rgp160 vaccine induces persistent cellular immune recognition as demonstrated by lymphocyte proliferation.
对参与杆状病毒表达的重组人免疫缺陷病毒1型（HIV-1）包膜糖蛋白（rgp160）疫苗I期试验的12名志愿者的淋巴细胞增殖反应进行了研究。6名受试者接受rgp160，另外3名受试者分别在0、1和6个月时接受重组乙型肝炎疫苗或安慰剂。rgp160和一种对照制剂，杆状病毒表达的重组HIV-1 p24，用作体外抗原。在第56天，所有接受rgp160的受试者的刺激指数（rgp160/rp24）均大于3.0，6名受试者中有5名的每分钟计数（cpm）差异大于1000。在所有未接受rgp160的6名受试者中，刺激指数小于2.0，cpm差异小于150。淋巴细胞增殖反应在初次免疫印迹反应性之前2周至5个月首次出现，并持续大于或等于540天，即使在失去可检测抗体的受试者中也是如此。因此，如淋巴细胞增殖所示，HIV-1 rgp160疫苗可诱导持续的细胞免疫识别。
